Hannah Valantine

Filings by Hannah Valantine span 3 companies, the busiest being BridgeBio Pharma, Inc., CareDx, Inc. and Pacific Biosciences of California, Inc. Between 1 July 2021 and 16 July 2026, the trades on record add up to 37 filings.

In open-market terms, that means 4 purchases worth €83k on one side and 7 sales worth €1.1M on the other. The totals exclude 3 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 13 share grants and 13 option exercises. 2026 to date brings no purchases and 5 sales.

The median purchase comes to €22k.

The latest filing, published on 17 July 2026, reports an option exercise of €136k in CareDx, Inc. The last insider purchase was made public on 30 June 2025, 475 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.